Related Experiment Video
Updated: Jun 26, 2025

Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study
Published on: April 18, 2025
Trends in Medicare utilization and reimbursement for hematology/oncology procedures from 2012 to 2023: A geriatric
1Department of Internal Medicine, Section of Geriatric Medicine Louisiana State University Health Sciences Center New Orleans Louisiana USA.
Insights
Medicare reimbursement for hematology/oncology procedures significantly declined between 2012 and 2023. This trend, adjusted for inflation, saw substantial decreases in compensation for common procedures.
Area of Science:
- Health Economics
- Oncology
- Hematology
Background:
- Limited data exists on reimbursement trends in hematology/oncology.
- Understanding these trends is crucial for practice sustainability and patient care.
Purpose of the Study:
- To analyze reimbursement trends for common hematology/oncology procedures from 2012 to 2023.
- To provide data-driven insights into the financial landscape of cancer care.
Main Methods:
- Utilized the Centers for Medicare and Medicaid Services' Physician Fee Schedule Look-Up Tool.
- Collected reimbursement data for 40 hematology/oncology procedure codes (2012-2023).
- Adjusted data to 2023 US dollars using the Consumer Price Index (CPI).
Main Results:
- Gross facility price reimbursement decreased by 4.4%; non-facility price increased by 9.2%.
- Inflation-adjusted compensation decreased by 96.1% (facility) and 96.6% (non-facility).
- No examined Current Procedural Terminology (CPT) codes showed an increase in net reimbursement.
Conclusions:
- Medicare reimbursement for key hematology/oncology procedures has decreased significantly from 2012 to 2023.
- These findings highlight potential financial challenges for oncology practices.
- Further research is needed to assess the impact on patient care delivery.
Objectives:
Given the scarcity of data exploring reimbursement trends in the field of hematology/oncology, we sought to characterize these trends for common procedures in this field from 2012 to 2023.
Methods:
Using the Centers for Medicare and Medicaid Services' Physician Fee Schedule Look-Up Tool we collected reimbursement data for 40 hematology/oncology procedure codes from 2012 to 2023. Data was adjusted to 2023 United States (US) dollars using the Consumer Price Index (CPI).
Results:
From 2012 to 2023 gross reimbursement for the facility price decreased 4.4% and increased 9.2% for the non-facility price. When adjusted for inflation, compensation decreased 96.1% and 96.6%, respectively. None of the 40 examined Current Procedural Terminology (CPT) codes increased in net reimbursement over the study period.
Conclusions:
Medicare reimbursement for common hematology/oncology procedures decreased from 2012 to 2023. Further research is necessary to explore the implications of these trends on the delivery of patient care.
More Related Videos
05:58Evaluation of a Point-of-Care Testing Analyzer for Measuring Peripheral Blood Leukocytes
Published on: March 22, 2022
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
Related Concept Videos
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Current Trends in Nursing I
Current Trends in Nursing II
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...